Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Current Liabilities: 2021-2024

Historic Total Current Liabilities for Krystal Biotech (KRYS) over the last 4 years, with Dec 2024 value amounting to $102.0 million.

  • Krystal Biotech's Total Current Liabilities rose 1.94% to $91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.3 million, marking a year-over-year increase of 1.94%. This contributed to the annual value of $102.0 million for FY2024, which is 208.20% up from last year.
  • Per Krystal Biotech's latest filing, its Total Current Liabilities stood at $102.0 million for FY2024, which was up 208.20% from $33.1 million recorded in FY2023.
  • Over the past 5 years, Krystal Biotech's Total Current Liabilities peaked at $102.0 million during FY2024, and registered a low of $25.7 million during FY2021.
  • In the last 3 years, Krystal Biotech's Total Current Liabilities had a median value of $33.1 million in 2023 and averaged $54.6 million.
  • Data for Krystal Biotech's Total Current Liabilities shows a peak YoY surged of 208.20% (in 2024) over the last 5 years.
  • Yearly analysis of 4 years shows Krystal Biotech's Total Current Liabilities stood at $25.7 million in 2021, then rose by 12.09% to $28.8 million in 2022, then rose by 14.72% to $33.1 million in 2023, then spiked by 208.20% to $102.0 million in 2024.